Mechanism-based pharmacokinetic–pharmacodynamic (PK–PD) modeling and simulation of oxaliplatin for hematological toxicity in rats

Population pharmacokinetics of oxaliplatin after intraperitoneal administration with hyperthermia in Wistar rats

(2018) M.I. Mas-Fuster et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Transit and lifespan in neutrophil production: implications for drug intervention

(2017) Daniel Câmara De Souza et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

Pathophysiology of Chemotherapy-Induced Peripheral Neuropathy

(2017) Hana Starobova et al.   Frontiers in Molecular Neuroscience

Population Pharmacokinetic–Pharmacodynamic Modeling of 5-Fluorouracil for Toxicities in Rats

(2016) Shinji Kobuchi et al.   EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS

Population pharmacokinetic analysis of oxaliplatin in adults and children identifies important covariates for dosing

(2015) Mina Nikanjam et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Population pharmacokinetics of peritoneal, plasma ultrafiltrated and protein-bound oxaliplatin concentrations in patients with disseminated peritoneal cancer after intraperitoneal hyperthermic chemoperfusion of oxaliplatin following cytoreductive surgery: correlation between oxaliplatin exposure and thrombocytopenia

(2014) Quentin Chalret du Rieu et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Characterization of Endogenous G-CSF and the Inverse Correlation to Chemotherapy-Induced Neutropenia in Patients with Breast Cancer Using Population Modeling

(2014) Angelica L. Quartino et al.   PHARMACEUTICAL RESEARCH

Semi-physiological pharmacokinetic–pharmacodynamic (PK–PD) modeling and simulation of 5-fluorouracil for thrombocytopenia in rats

(2014) Shinji Kobuchi et al.   XENOBIOTICA

Semi-physiological pharmacokinetic–pharmacodynamic modeling and simulation of 5-fluorouracil for the whole time course of alterations in leukocyte, neutrophil and lymphocyte counts in rats

(2014) Shinji Kobuchi et al.   XENOBIOTICA

Pharmacokinetic–pharmacodynamic (PK–PD) modeling and simulation of 5-fluorouracil for erythropenia in rats

(2014) Shinji Kobuchi et al.   JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS

Oxaliplatin-related thrombocytopenia

(2012) D. L. Jardim et al.   ANNALS OF ONCOLOGY

Pharmacokinetics and Toxicodynamics of Oxaliplatin in Rats: Application of a Toxicity Factor to Explain Differences in the Nephrotoxicity and Myelosuppression Induced by Oxaliplatin and the Other Platinum Antitumor Derivatives

(2010) Kazuhiko Hanada et al.   PHARMACEUTICAL RESEARCH

Scaling the time-course of myelosuppression from rats to patients with a semi-physiological model

(2009) Lena E. Friberg et al.   INVESTIGATIONAL NEW DRUGS

Oxaliplatin-induced immune mediated thrombocytopenia

(2008) Muhammad S. Beg et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY